Neuroendocrine dysregulation and the growth hormone–IGF-1 axis in anorexia nervosa

References

• The American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) (4th Edition). American Psychiatric Publishing, VA, USA (1994).
   Google Scholar
• Harrison G Pope Jr, Hudson JI, Yurgelun-Todd D, Hudson MS. Prevalence of anorexia nervosa and bulimia in three student populations. Int. J. Eat. Disord.3, 45–51 (1984).
   Web of Science ®Google Scholar
• Lucas AR, Crowson CS, O’Fallon WM, Melton LJ 3rd. The ups and downs of anorexia nervosa. Int. J. Eat. Disord.26(4), 397–405 (1999).
   PubMed Web of Science ®Google Scholar
• Miller KK, Grinspoon SK, Ciampa J, Hier J, Herzog D, Klibanski A. Medical findings in outpatients with anorexia nervosa. Arch. Intern. Med.165(5), 561–566 (2005).
   PubMedGoogle Scholar
• Grinspoon S, Thomas E, Pitts S et al. Prevalence and predictive factors for regional osteopenia in women with anorexia nervosa. Ann. Intern. Med.133(10), 790–794 (2000).
   PubMed Web of Science ®Google Scholar
• Rigotti NA, Neer RM, Skates SJ, Herzog DB, Nussbaum SR. The clinical course of osteoporosis in anorexia nervosa. A longitudinal study of cortical bone mass. JAMA265(9), 1133–1138 (1991).
   PubMed Web of Science ®Google Scholar
• Boyar RM, Katz J, Finkelstein JW et al. Anorexia nervosa. Immaturity of the 24-hour luteinizing hormone secretory pattern. N. Engl. J. Med.291(17), 861–865 (1974).
   PubMed Web of Science ®Google Scholar
• Wiegelmann W, Solbach HG. Effects of LH-RH on plasma levels of LH and FSH in anorexia nervosa. Horm. Metab. Res.4(5), 404 (1972).
   PubMed Web of Science ®Google Scholar
• Mecklenburg RS, Loriaux DL, Thompson RH, Andersen AE, Lipsett MB. Hypothalamic dysfunction in patients with anorexia nervosa. Medicine (Baltimore)53(2), 147–159 (1974).
   PubMed Web of Science ®Google Scholar
• Travaglini P, Beck-Peccoz P, Ferrari C et al. Some aspects of hypothalamic–pituitary function in patients with anorexia nervosa. Acta Endocrinol. (Copenh.).81(2), 252–262 (1976).
   PubMedGoogle Scholar
• Grinspoon S, Gulick T, Askari H et al. Serum leptin levels in women with anorexia nervosa. J. Clin. Endocrinol. Metab.81(11), 3861–3863 (1996).
   PubMed Web of Science ®Google Scholar
• Misra M, Miller KK, Kuo K et al. Secretory dynamics of leptin in adolescent girls with anorexia nervosa and healthy adolescents. Am. J. Physiol. Endocrinol. Metab.289(3), E373–E381 (2005).
   Web of Science ®Google Scholar
• Miller KK, Grinspoon S, Gleysteen S et al. Preservation of neuroendocrine control of reproductive function despite severe undernutrition. J. Clin. Endocrinol. Metab.89(9), 4434–4438 (2004).
   PubMed Web of Science ®Google Scholar
• Welt CK, Chan JL, Bullen J et al. Recombinant human leptin in women with hypothalamic amenorrhea. N. Engl. J. Med.351(10), 987–997 (2004).
   PubMed Web of Science ®Google Scholar
• van Binsbergen CJ, Coelingh Bennink HJ, Odink J, Haspels AA, Koppeschaar HP. A comparative and longitudinal study on endocrine changes related to ovarian function in patients with anorexia nervosa. J. Clin. Endocrinol. Metab.71(3), 705–711 (1990).
   PubMed Web of Science ®Google Scholar
• Miller KK, Lawson EA, Mathur V et al. Androgens in women with anorexia nervosa and normal-weight women with hypothalamic amenorrhea. J. Clin. Endocrinol. Metab.92(4), 1334–1339 (2007).
   PubMed Web of Science ®Google Scholar
• Klibanski A, Biller BM, Schoenfeld DA, Herzog DB, Saxe VC. The effects of estrogen administration on trabecular bone loss in young women with anorexia nervosa. J. Clin. Endocrinol. Metab.80(3), 898–904 (1995).
   PubMed Web of Science ®Google Scholar
• Grinspoon S, Thomas L, Miller K, Herzog D, Klibanski A. Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa. J. Clin. Endocrinol. Metab.87(6), 2883–2891 (2002).
   PubMed Web of Science ®Google Scholar
• Miller KK, Meenaghan E, Lawson EA et al. Effects of risedronate and low-dose transdermal testosterone on bone mineral density in women with anorexia nervosa: a randomized, placebo-controlled study. J. Clin. Endocrinol. Metab.96(7), 2081–2088 (2011).
   PubMed Web of Science ®Google Scholar
• Misra M, Miller KK, Almazan C et al. Alterations in cortisol secretory dynamics in adolescent girls with anorexia nervosa and effects on bone metabolism. J. Clin. Endocrinol. Metab.89(10), 4972–4980 (2004).
   PubMed Web of Science ®Google Scholar
• Boyar RM, Hellman LD, Roffwarg H et al. Cortisol secretion and metabolism in anorexia nervosa. N. Engl. J. Med.296(4), 190–193 (1977).
   PubMed Web of Science ®Google Scholar
• Misra M, Klibanski A. The neuroendocrine basis of anorexia nervosa and its impact on bone metabolism. Neuroendocrinology93(2), 65–73 (2011).
   PubMed Web of Science ®Google Scholar
• Canalis E. Clinical review 83: mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis. J. Clin. Endocrinol. Metab.81(10), 3441–3447 (1996).
   PubMed Web of Science ®Google Scholar
• Urena P, Iida-Klein A, Kong XF et al. Regulation of parathyroid hormone (PTH)/PTH-related peptide receptor messenger ribonucleic acid by glucocorticoids and PTH in ROS 17/2.8 and OK cells. Endocrinology134(1), 451–456 (1994).
   PubMed Web of Science ®Google Scholar
• McCarthy TL, Centrella M, Canalis E. Cortisol inhibits the synthesis of insulin-like growth factor-I in skeletal cells. Endocrinology126(3), 1569–1575 (1990).
   PubMed Web of Science ®Google Scholar
• Padmanabhan V, Keech C, Convey EM. Cortisol inhibits and adrenocorticotropin has no effect on luteinizing hormone-releasing hormone-induced release of luteinizing hormone from bovine pituitary cells in vitro. Endocrinology112(5), 1782–1787 (1983).
   PubMed Web of Science ®Google Scholar
• Lawson EA, Donoho D, Miller KK et al. Hypercortisolemia is associated with severity of bone loss and depression in hypothalamic amenorrhea and anorexia nervosa. J. Clin. Endocrinol. Metab.94(12), 4710–4716 (2009).
   PubMed Web of Science ®Google Scholar
• Moshang T Jr, Parks JS, Baker L et al. Low serum triiodothyronine in patients with anorexia nervosa. J. Clin. Endocrinol. Metab.40(3), 470–473 (1975).
   PubMed Web of Science ®Google Scholar
• Miyai K, Yamamoto T, Azukizawa M, Ishibashi K, Kumahara Y. Serum thyroid hormones and thyrotropin in anorexia nervosa. J. Clin. Endocrinol. Metab.40(2), 334–338 (1975).
   PubMed Web of Science ®Google Scholar
• Croxson MS, Ibbertson HK. Low serum triiodothyronine (T3) and hypothyroidism in anorexia nervosa. J. Clin. Endocrinol. Metab.44(1), 167–174 (1977).
   PubMed Web of Science ®Google Scholar
• Leslie RD, Isaacs AJ, Gomez J, Raggatt PR, Bayliss R. Hypothalamo–pituitary–thyroid function in anorexia nervosa: influence of weight gain. Br. Med. J.2(6136), 526–528 (1978).
   PubMed Web of Science ®Google Scholar
• Casper RC, Frohman LA. Delayed TSH release in anorexia nervosa following injection of thyrotropin-releasing hormone (TRH). Psychoneuroendocrinology7(1), 59–68 (1982).
   PubMed Web of Science ®Google Scholar
• Kiyohara K, Tamai H, Takaichi Y, Nakagawa T, Kumagai LF. Decreased thyroidal triiodothyronine secretion in patients with anorexia nervosa: influence of weight recovery. Am. J. Clin. Nutr.50(4), 767–772 (1989).
   PubMed Web of Science ®Google Scholar
• Moore R, Mills IH. Serum T3 and T4 levels in patients with anorexia nervosa showing transient hyperthyroidism during weight gain. Clin. Endocrinol. (Oxf.).10(5), 443–449 (1979).
   PubMed Web of Science ®Google Scholar
• Onur S, Haas V, Bosy-Westphal A et al.L-tri-iodothyronine is a major determinant of resting energy expenditure in underweight patients with anorexia nervosa and during weight gain. Eur. J. Endocrinol.152(2), 179–184 (2005).
   PubMed Web of Science ®Google Scholar
• Miell JP, Taylor AM, Zini M, Maheshwari HG, Ross RJ, Valcavi R. Effects of hypothyroidism and hyperthyroidism on insulin-like growth factors (IGFs) and growth hormone- and IGF-binding proteins. J. Clin. Endocrinol. Metab.76(4), 950–955 (1993).
   PubMed Web of Science ®Google Scholar
• Kindblom JM, Gevers EF, Skrtic SM et al. Increased adipogenesis in bone marrow but decreased bone mineral density in mice devoid of thyroid hormone receptors. Bone36(4), 607–616 (2005).
   PubMed Web of Science ®Google Scholar
• Bredella MA, Fazeli PK, Miller KK et al. Increased bone marrow fat in anorexia nervosa. J. Clin. Endocrinol. Metab.94(6), 2129–2136 (2009).
   PubMed Web of Science ®Google Scholar
• Brent GA. Tissue-specific actions of thyroid hormone: insights from animal models. Rev. Endocr. Metab. Disord.1(1–2), 27–33 (2000).
   PubMedGoogle Scholar
• Scacchi M, Pincelli AI, Caumo A et al. Spontaneous nocturnal growth hormone secretion in anorexia nervosa. J. Clin. Endocrinol. Metab.82(10), 3225–3229 (1997).
   PubMed Web of Science ®Google Scholar
• Stoving RK, Veldhuis JD, Flyvbjerg A et al. Jointly amplified basal and pulsatile growth hormone (GH) secretion and increased process irregularity in women with anorexia nervosa: indirect evidence for disruption of feedback regulation within the GH-insulin-like growth factor I axis. J. Clin. Endocrinol. Metab.84(6), 2056–2063 (1999).
   PubMed Web of Science ®Google Scholar
• Misra M, Miller KK, Bjornson J et al. Alterations in growth hormone secretory dynamics in adolescent girls with anorexia nervosa and effects on bone metabolism. J. Clin. Endocrinol. Metab.88(12), 5615–5623 (2003).
   PubMed Web of Science ®Google Scholar
• Otto B, Cuntz U, Fruehauf E et al. Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. Eur. J. Endocrinol.145(5), 669–673 (2001).
   PubMed Web of Science ®Google Scholar
• Grinspoon SK, Baum HB, Peterson S, Klibanski A. Effects of rhIGF-I administration on bone turnover during short-term fasting. J. Clin. Invest.96(2), 900–906 (1995).
   PubMed Web of Science ®Google Scholar
• Hotta M, Fukuda I, Sato K, Hizuka N, Shibasaki T, Takano K. The relationship between bone turnover and body weight, serum insulin-like growth factor (IGF) I, and serum IGF-binding protein levels in patients with anorexia nervosa. J. Clin. Endocrinol. Metab.85(1), 200–206 (2000).
   PubMed Web of Science ®Google Scholar
• Counts DR, Gwirtsman H, Carlsson LM, Lesem M, Cutler GB Jr. The effect of anorexia nervosa and refeeding on growth hormone-binding protein, the insulin-like growth factors (IGFs), and the IGF-binding proteins. J. Clin. Endocrinol. Metab.75(3), 762–767 (1992).
   PubMed Web of Science ®Google Scholar
• Fazeli PK, Misra M, Goldstein M, Miller KK, Klibanski A. Fibroblast growth factor-21 may mediate growth hormone resistance in anorexia nervosa. J. Clin. Endocrinol. Metab.95(1), 369–374 (2010).
   PubMed Web of Science ®Google Scholar
• Nishimura T, Nakatake Y, Konishi M, Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim. Biophys. Acta1492(1), 203–206 (2000).
   PubMed Web of Science ®Google Scholar
• Zhang X, Yeung DC, Karpisek M et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes57(5), 1246–1253 (2008).
   PubMed Web of Science ®Google Scholar
• Mraz M, Bartlova M, Lacinova Z et al. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with Type 2 diabetes and obesity. Clin. Endocrinol. (Oxf.).71(3), 369–375 (2009).
   PubMed Web of Science ®Google Scholar
• Rodriguez JC, Gil-Gomez G, Hegardt FG, Haro D. Peroxisome proliferator-activated receptor mediates induction of the mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase gene by fatty acids. J. Biol. Chem.269(29), 18767–18772 (1994).
   PubMed Web of Science ®Google Scholar
• Inagaki T, Dutchak P, Zhao G et al. Endocrine regulation of the fasting response by PPARα-mediated induction of fibroblast growth factor 21. Cell Metab.5(6), 415–425 (2007).
   PubMed Web of Science ®Google Scholar
• Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARα and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab.5(6), 426–437 (2007).
   PubMed Web of Science ®Google Scholar
• Inagaki T, Lin VY, Goetz R, Mohammadi M, Mangelsdorf DJ, Kliewer SA. Inhibition of growth hormone signaling by the fasting-induced hormone FGF21. Cell Metab.8(1), 77–83 (2008).
   PubMed Web of Science ®Google Scholar
• Canalis E. Effect of insulinlike growth factor I on DNA and protein synthesis in cultured rat calvaria. J. Clin. Invest.66(4), 709–719 (1980).
   PubMed Web of Science ®Google Scholar
• Nakasaki M, Yoshioka K, Miyamoto Y, Sasaki T, Yoshikawa H, Itoh K. IGF-I secreted by osteoblasts acts as a potent chemotactic factor for osteoblasts. Bone43(5), 869–879 (2008).
   PubMed Web of Science ®Google Scholar
• Grinspoon S, Baum H, Lee K, Anderson E, Herzog D, Klibanski A. Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa. J. Clin. Endocrinol. Metab.81(11), 3864–3870 (1996).
   PubMed Web of Science ®Google Scholar
• Misra M, McGrane J, Miller KK et al. Effects of rhIGF-1 administration on surrogate markers of bone turnover in adolescents with anorexia nervosa. Bone45(3), 493–498 (2009).
   PubMed Web of Science ®Google Scholar
• Slootweg MC, van Buul-Offers SC, Herrmann-Erlee MP, Duursma SA. Direct stimulatory effect of growth hormone on DNA synthesis of fetal chicken osteoblasts in culture. Acta Endocrinol. (Copenh.).118(2), 294–300 (1988).
   PubMedGoogle Scholar
• Kassem M, Blum W, Ristelli J, Mosekilde L, Eriksen EF. Growth hormone stimulates proliferation and differentiation of normal human osteoblast-like cells in vitro. Calcif. Tissue Int.52(3), 222–226 (1993).
   PubMed Web of Science ®Google Scholar
• Marcus R, Butterfield G, Holloway L et al. Effects of short term administration of recombinant human growth hormone to elderly people. J. Clin. Endocrinol. Metab.70(2), 519–527 (1990).
   PubMed Web of Science ®Google Scholar
• Baum HB, Biller BM, Finkelstein JS et al. Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Ann. Intern. Med.125(11), 883–890 (1996).
   PubMed Web of Science ®Google Scholar
• Bravenboer N, Holzmann PJ, ter Maaten JC, Stuurman LM, Roos JC, Lips P. Effect of long-term growth hormone treatment on bone mass and bone metabolism in growth hormone-deficient men. J. Bone Miner. Res.20(10), 1778–1784 (2005).
   PubMed Web of Science ®Google Scholar
• Snyder PJ, Biller BM, Zagar A et al. Effect of growth hormone replacement on BMD in adult-onset growth hormone deficiency. J. Bone Miner. Res.22(5), 762–770 (2007).
   PubMed Web of Science ®Google Scholar
• Fazeli PK, Lawson EA, Prabhakaran R et al. Effects of recombinant human growth hormone in anorexia nervosa: a randomized, placebo-controlled study. J. Clin. Endocrinol. Metab.95(11), 4889–4897 (2010).
   PubMed Web of Science ®Google Scholar
• Salomon F, Cuneo RC, Hesp R, Sonksen PH. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N. Engl. J. Med.321(26), 1797–1803 (1989).
   PubMed Web of Science ®Google Scholar
• Mauras N, O’Brien KO, Welch S et al. Insulin-like growth factor I and growth hormone (GH) treatment in GH-deficient humans: differential effects on protein, glucose, lipid, and calcium metabolism. J. Clin. Endocrinol. Metab.85(4), 1686–1694 (2000).
   PubMed Web of Science ®Google Scholar
• Mauras N, Martinez V, Rini A, Guevara-Aguirre J. Recombinant human insulin-like growth factor I has significant anabolic effects in adults with growth hormone receptor deficiency: studies on protein, glucose, and lipid metabolism. J. Clin. Endocrinol. Metab.85(9), 3036–3042 (2000).
   PubMed Web of Science ®Google Scholar
• Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature402(6762), 656–660 (1999).
   PubMed Web of Science ®Google Scholar
• Misra M, Miller KK, Herzog DB et al. Growth hormone and ghrelin responses to an oral glucose load in adolescent girls with anorexia nervosa and controls. J. Clin. Endocrinol. Metab.89(4), 1605–1612 (2004).
   PubMed Web of Science ®Google Scholar
• Misra M, Miller KK, Kuo K et al. Secretory dynamics of ghrelin in adolescent girls with anorexia nervosa and healthy adolescents. Am. J. Physiol. Endocrinol. Metab.289(2), E347–E356 (2005).
   Google Scholar
• Zhao TJ, Liang G, Li RL et al. Ghrelin O-acyltransferase (GOAT) is essential for growth hormone-mediated survival of calorie-restricted mice. Proc. Natl Acad Sci. USA107(16), 7467–7472 (2010).
   PubMed Web of Science ®Google Scholar
• Fukushima N, Hanada R, Teranishi H et al. Ghrelin directly regulates bone formation. J. Bone Miner. Res.20(5), 790–798 (2005).
   PubMed Web of Science ®Google Scholar
• Misra M, Miller KK, Stewart V et al. Ghrelin and bone metabolism in adolescent girls with anorexia nervosa and healthy adolescents. J. Clin. Endocrinol. Metab.90(9), 5082–5087 (2005).
   PubMed Web of Science ®Google Scholar
• Misra M, Prabhakaran R, Miller KK et al. Prognostic indicators of changes in bone density measures in adolescent girls with anorexia nervosa-II. J. Clin. Endocrinol. Metab.93(4), 1292–1297 (2008).
   PubMed Web of Science ®Google Scholar
• Utz AL, Lawson EA, Misra M et al. Peptide YY (PYY) levels and bone mineral density (BMD) in women with anorexia nervosa. Bone43(1), 135–139 (2008).
   PubMed Web of Science ®Google Scholar
• Misra M, Miller KK, Tsai P et al. Elevated peptide YY levels in adolescent girls with anorexia nervosa. J. Clin. Endocrinol. Metab.91(3), 1027–1033 (2006).
   PubMed Web of Science ®Google Scholar
• Baldock PA, Sainsbury A, Couzens M et al. Hypothalamic Y2 receptors regulate bone formation. J. Clin. Invest.109(7), 915–921 (2002).
   PubMed Web of Science ®Google Scholar
• Lloyd B, Ravi P, Mendes N, Klibanski A, Misra M. Peptide YY levels across pubertal stages and associations with growth hormone. J. Clin. Endocrinol. Metab.95(6), 2957–2962 (2010).
   PubMed Web of Science ®Google Scholar
• Legroux-Gerot I, Vignau J, Biver E et al. Anorexia nervosa, osteoporosis and circulating leptin: the missing link. Osteoporos. Int.21(10), 1715–1722 (2010).
   PubMed Web of Science ®Google Scholar
• Lawson EA, Miller KK, Bredella MA et al. Hormone predictors of abnormal bone microarchitecture in women with anorexia nervosa. Bone46(2), 458–463 (2010).
   PubMed Web of Science ®Google Scholar
• Misra M, Miller KK, Cord J et al. Relationships between serum adipokines, insulin levels, and bone density in girls with anorexia nervosa. J. Clin. Endocrinol. Metab.92(6), 2046–2052 (2007).
   PubMed Web of Science ®Google Scholar
• Tagami T, Satoh N, Usui T, Yamada K, Shimatsu A, Kuzuya H. Adiponectin in anorexia nervosa and bulimia nervosa. J. Clin. Endocrinol. Metab.89(4), 1833–1837 (2004).
   PubMed Web of Science ®Google Scholar
• Housova J, Anderlova K, Krizova J et al. Serum adiponectin and resistin concentrations in patients with restrictive and binge/purge form of anorexia nervosa and bulimia nervosa. J. Clin. Endocrinol. Metab.90(3), 1366–1370 (2005).
   PubMed Web of Science ®Google Scholar
• Luo XH, Guo LJ, Xie H et al. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. J. Bone Miner. Res.21(10), 1648–1656 (2006).
   PubMed Web of Science ®Google Scholar